Trial Profile
A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 26 May 2016 Status changed from completed to discontinued.
- 26 May 2016 Status changed from completed to discontinued.
- 30 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.